Recommendation of the President – cholestyramine
On 13 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 4/2025 on the appropriateness of authorizing the reimbursement of medicinal products containing cholestyramine for the indications: Chronic diarrhea; Hirschsprung’s disease; Crohn’s disease; severe intestinal malabsorption caused by: resection of a segment of the small intestine, enterostomy; dyslipidemia, including hypercholesterolemia in patients who cannot receive statins; primary biliary cirrhosis; primary sclerosing cholangitis; pruritus in the course of: Alagille syndrome, cholestatic drug-induced hepatitis, intrahepatic cholestasis, resection of part of the large intestine; secondary cirrhosis with features of cholestasis following HCV infection
Publication in Public Information Bulletin (BIP) >>